I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

被引：0
|
作者：
Zhong-Ke Chen
Jing Fan
Fen-Qiang Li
Shi-Yan Zhou
Yuan-Shun Xu
机构：
[1] Affiliated Hospital of Gansu Medical College,Department of Interventional Therapy
[2] Lanzhou University First Affiliated Hospital,Interventional Radiology Department
[3] Xuzhou Central Hospital,Radiology Department
来源：
Journal of Cardiothoracic Surgery | / 17卷
关键词：
I-125 seed; Non-small-cell lung cancer; Progressive; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Role of preoperative chemotherapy for non-small-cell lung cancer: A meta-analysis
    Nakamura, Haruhiko
    Kawasaki, Norihito
    Taguchi, Masahiko
    Kabasawa, Kazuyuki
    LUNG CANCER, 2006, 54 (03) : 325 - 329
  • [22] Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
    da Silveira Nogueira Lima, Joao Paulo
    dos Santos, Lucas Vieira
    Sasse, Emma Chen
    Sasse, Andre Deeke
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) : 601 - 607
  • [23] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
    Liang, Wenhua
    Zhang, Yaxiong
    Kang, Shiyang
    Pan, Hui
    Shao, Wenlong
    Deng, Qiuhua
    Shi, Xiaoshun
    Wang, Wei
    He, Jianxing
    JOURNAL OF THORACIC DISEASE, 2014, 6 (09) : 1239 - 1250
  • [24] Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer
    Chen, Jianxin
    Wang, Junhui
    Wu, Xilin
    Che, Xiaoling
    Zou, Yan
    Weng, Meiling
    Miao, Qian
    Zheng, Qinhong
    FUTURE ONCOLOGY, 2017, 13 (24) : 2195 - 2207
  • [25] Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis
    Luo, Long
    Hu, Qian
    Jiang, Jun-xia
    Yang, Xing
    Dinglin, Xiao-xiao
    Lin, Xiao
    Yao, He-rui
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (03) : 253 - 261
  • [26] Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
    Park, Hyung Soon
    Lim, Sun Min
    Shin, Ho Jung
    Cho, Arthur
    Shin, Jae-Gook
    Lee, Min Goo
    Kim, Hye Ryun
    Kim, Joo Hang
    Cho, Byoung Chul
    PHARMACOGENETICS AND GENOMICS, 2016, 26 (03) : 116 - 125
  • [27] First-line treatment of advanced ALK-positive non-small-cell lung cancer
    Gandhi, Shipra
    Chen, Hongbin
    Zhao, Yujie
    Dy, Grace K.
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
  • [28] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    Kao, Hsiang-Fong
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003
  • [29] The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis
    Zhang, Lei
    Ren, Hong-Wei
    Wu, Qi-Long
    Wu, Yan-Juan
    Song, Xiang
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (02) : 1137 - 1143
  • [30] Traditional herbal medicine combined with first-line platinum-based chemotherapy for advanced non-small-cell lung cancer A PRISMA-compliant systematic review and meta-analysis
    Jin, Hayun
    Park, Su Bin
    Yoon, Jee-Hyun
    Lee, Jee Young
    Kim, Eun Hye
    Yoon, Seong Woo
    MEDICINE, 2021, 100 (37)
12345